SecBot SecBot
← Back to Analyst Consensus
MPLT Buy

MapLight Therapeutics, Inc.

Current Price —
Implied Upside —
Analysts 20

30-Day Momentum

▲ 1 upgrades  /  ▼ 0 downgrades  /  0 reiterations  from 1 firms

Rating Timeline

Date ▼FirmActionFrom → To RatingPrice TargetFirm Rating
Oct 6, 2026Guggenheiminitiate— → Neutral—52%
Aug 31, 2026NeedhammaintainBuy → Buy—50%
Aug 10, 2026UBSdowngradeBuy → Neutral—54%
Jul 28, 2026Canaccord GenuitymaintainBuy → Buy—48%
Jul 28, 2026Morgan StanleydowngradeOverweight → Equal-Weight—54%
Jul 28, 2026HC Wainwright & Co.maintainBuy → Buy—44%
Jul 24, 2026Canaccord GenuitymaintainBuy → Buy—48%
Jul 21, 2026UBSmaintainBuy → Buy—54%
Jul 21, 2026BMO Capitalinitiate— → Outperform—53%
Jul 10, 2026NeedhammaintainBuy → Buy—50%
Jun 25, 2026Raymond Jamesinitiate— → Strong Buy—53%
Jun 23, 2026Craig-HallummaintainBuy → Buy—54%
Jun 22, 2026NeedhammaintainBuy → Buy—50%
Jun 2, 2026StifelmaintainBuy → Buy—53%
May 28, 2026HC Wainwright & Co.reiterateBuy → Buy—44%
May 27, 2026UBSinitiate— → Buy—54%
May 21, 2026Craig-Halluminitiate— → Buy—54%
May 4, 2026HC Wainwright & Co.initiate— → Buy—44%
Apr 8, 2026Needhaminitiate— → Buy—50%
Apr 7, 2026TD Coweninitiate— → Buy—54%
Mar 19, 2026Canaccord Genuityinitiate— → Buy$3548%
Nov 21, 2025Jefferiesinitiate— → Buy$3251%
Nov 21, 2025Leerink Partnersinitiate— → Outperform$3051%
Nov 21, 2025Stifelinitiate— → Buy$2853%
Nov 21, 2025Morgan Stanleyinitiate— → Overweight$3454%

Price Target Trend

May 19, 2026 Oct 27, 2026

EPS Estimates

0q —
+1y —
+1q —
0y —

Cross-Platform Signals

No cross-platform signals in the last 90 days

Fresh Analyst Detail

Price targets, earnings estimates, and firm actions for this ticker — updated within the last 24 hours.

Subscribe for Full Access